Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's ...
In the months after the 2024 election and before President Donald Trump’s second inauguration, healthcare executives paid ...
14h
Medpage Today on MSNHealth Execs Showered Trump With Millions; CDC Data Altered; Healthcare BankruptciesValentina Dabos, lead author of the tracker, said in a statement that the consequences of bankruptcies in healthcare "can be ...
Pfizer CEO Albert Bourla said its manufacturing business could be vulnerable from President Donald Trump’s tariffs in Europe ...
Pfizer CEO has met with the new administration and believes Trump and RFK Jr. are going to be net positives for the health ...
Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's "radical" changes.
Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.
Fortune on MSN14d
The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and MerckPfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
While the exact date of the meeting was not disclosed, Bourla said he and the health secretary nominee chatted civilly, conversing on topics they agreed on rather than straying to more divisive ...
As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...
Pfizer’s chief executive said he was “disappointed” with Robert F Kennedy Jr’s refusal to disavow the debunked link between vaccines and autism, even as he expressed confidence that the Trump ...
Welcome to the Wall Street Week newsletter, bringing you stories of capitalism about things you need to know, but even more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results